Safety of Microstimulator During Radiation Therapy - A Preliminary Study on Head and Neck Cancer Patients

Uttam K. Sinha1, Brenda Villegas2, Kuo C2, Frances J. Richmond2, Rizwan Masood3, Nora I. Nelson1 and Gerald E. Loeb1

1Department of Otolarngology-Head and Neck Surgery, Keck School of Medicine, USA
2Regulatory Science Program, School of Pharmacy, USA
3Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, USA

Corresponding author: Uttam K. Sinha, MS, MD, FACS, Medical Director, Head and Neck Surgery, Associate Dean, Surgical Simulation Watt Chair, Head and Neck Cancer Research Keck Medical Center, University of Southern California 1540 Alcazar St, Room 204M, Los Angeles, California 90601, USA, Tel: 323 442.5790; Fax: 323 442.5820; E-mail: sinha@usc.edu

Received date: Jul 22, 2014, Accepted date: Oct 30, 2014, Publication date: Nov 03, 2014

Abstract

Objectives: To determine the safety and performance of miniature neuromuscular stimulator called MicroStimulator (MS) during radiation therapy (RT) of head and neck cancer (HNC).

Study Design: Pilot study

Methods: Four patients who underwent modified radical neck dissection for HNC received MS implants. The implant was placed 2-3 mm above and parallel to the hypoglossal nerve. All patients had tracheotomy and gastric tubes placed during surgery. Stimulation thresholds were obtained in three patients and electrical exercise programs were initiated in two patients. One patient completed the study, started RT and stimulation of the MS 3-4 weeks after surgery. The implant was energized and controlled by a radio frequency magnetic field from an external coil placed near the implant. Patients underwent stimulation of the MS one hour per day using intermittent trains of stimuli generating fused, maximal contractions.

Results: No postoperative or implant specific complication was noted. All patients required and tolerated stimulation without pain or discomfort. Visible contraction of muscles of swallowing was noted in both patients during stimulation indicating that MS remained functional during RT. All patients used the device at home and maintained their oral feeding and weight. None had aspiration pneumonia.

Conclusions: MS appears to be a safe device for stimulation of swallowing muscles during MS for HNC. Implant performance is not affected by RT. It effectively stimulates the nerves to induce robust contraction of muscles of swallowing and laryngeal elevation. High patient compliance was achieved with this implant.

Keywords: Head and neck cancer; MicroStimulator, Radiation therapy; Quality of life; Traditional swallowing therapy

Introduction

In the pursuit of improving the management of head and neck squamous cell carcinoma (HNC) there has been intensification of radiation therapy (RT) by concurrent delivery of chemotherapy (CT) and altered fractionated RT, notably accelerated regimens [1,2]. These approaches intensify the tumoricidal effects of RT [3]. However, the radiation sensitizing effects of CT lead to increased acute toxicity (e.g. mucositis) and late complications (e.g. fibrosis, stenosis) [4]. Excessive mucositis, fibrosis and reduced motility of the swallowing muscles lead to dysphagia observed following chemoradiation therapy (CRT) [5]. Dysphagia is chronic in nature and has the most detrimental effect on quality of life (QOL). A more serious problem related to dysphagia is silent aspiration, a condition that can cause death. Late pharyngeal toxicity of CRT has recently been recognized as the main barrier to winning the battle with HNC [6]. A prospective cohort study and cross-sectional quality of life (QOL) analysis showed that implementation of pretreatment traditional swallowing therapy (TST) may improve dysphagia specific QOL in HNC patients undergoing CRT [7,8].

A continuous challenge faced by the clinician and patient is compliance with a daily exercise program of TST. We developed a new protocol in our institution for management of dysphagia in patients with HNC (this issue). They undergo TST and transcutaneous neuromuscular electrical stimulation (tNMES) for 1 hour twice a week during CRT. Stimulation via surface electrodes has limitations because of the amount of cutaneous stimulation that patients will tolerate and adjust the stimulus parameters. In addition, patient and family spend four to five hours (including commute time) for each therapy session. To improve the efficacy and ease of NMES treatment, we employed an implantable platform technology called MicroStimulator (MS) [9], which can be used to treat neuromuscular disorders effectively at home (Figure 1).
A variety of mechanisms are responsible for improvement in swallowing function by NMES therapy. Studies have shown that electrical stimulation increases the local blood flow and reduces the extracellular fluid resulting in decreased edema in the tissues [10]. In addition, NMES selectively activates both type I and type II muscle fibers [11]. The type II fibers are involved in the high-speed forceful contractions of several muscles involved in swallowing [11]. Type II fibers are the first to undergo disuse atrophy but they respond well to electrically induced exercise. Thus therapy directed at type II muscle fibers involved in swallowing should improve swallowing functions in HNC patients with dysphagia. Stimulation of a muscle nerve will elicit centrally propagated activity in large diameter proprioceptive afferents such as from muscle spindles and Golgi tendon organs and antidromic conduction in motor axon collaterals to Renshaw interneurons. Functional magnetic resonance imaging studies of the sensory cortex in stroke patients demonstrate increase in intensity in sensory cortex following similar stimulation of the arm muscles [12,13]. Such ascending activity may facilitate cortical plasticity that helps to maintain or recover voluntary function. Finally, recent data from our laboratory demonstrated that NMES with traditional swallow therapy (TST) reduces fibrosis in the muscles of laryngeal elevation after radiation therapy (RT), and improves dysphagia in HNC patients. RT causes overexpressions of TGF-β1, which in turn downregulates the expression of Myo-D gene through Smad3 signaling pathway. Normal expression of Myo-D is important to maintain function of cervical muscles. NMES with TST restores this signaling pathway, reduces fibrosis and improves dysphagia in HNC patients [14].

The purpose of this study is to establish the safety, to optimize the surgical placement and stimulation parameters, and to determine the performance of the implant during CRT.

**Materials and Methods**

**Microstimulator**

Microstimulators are a new class of generic wireless devices that can be injected into muscles and near nerves to deliver precisely metered stimulation pulses (Alfred E. Mann Foundation for Scientific Research, Valencia, CA). These injectable, wireless MS receive power and command signals by inductive coupling from an external antenna [15-17]. Four generations of this technology are now either in clinical trials or under development [9,18,19]. All are designed to stimulate myelinated sensory or motor axons, typically in peripheral nerves or muscles (Figure 1).

The implants are designed to stimulate myelinated sensory or motor axons, typically in peripheral nerves or muscles. MS has been approved for and used in clinical investigational studies in the U.S., Canada and Italy [9,18,19]. The electronic components of the implant are housed in a hermetically sealed glass capsule, 2mm diameter x 16 mm long. Each device delivers monophasic stimulation pulses (0.5–31.5 mA, 8-512 μs) through a tantalum capacitor electrode, which is immediately recharged to the compliance voltage in order to maintain the charge-balance required for safe chronic use in the body. The counter-electrode is made from pure iridium, which forms a conductive, non-polarizing oxide that can be used safely to deliver maximal stimulus pulses [20]. The unpowered implant is an inert foreign body that can be left in place indefinitely when no longer required [21].

MSs are safe in a radiation field. Implantable Technology Testing: Three MSs were implanted in Filet mignon at different orientation as shown in Figure 2 and were exposed to radiation therapy twice with dose of 70 Gy using 137 CS source, gamma cell 40. The MS implants were extracted out from the Filet mignon and tested for their electrical performance and reliability.

**Patient Selection**

The study was performed following approval by the Institutional Review Board and in accordance with Good Clinical Practice under the Investigational Device Exemption from the United States Food and Drug Administration (FDA). All patients underwent a modified
radical neck dissection (MRND) for HNC. During MRND, the implant was placed 2-3 mm above and parallel to the hypoglossal nerve and secured in position using absorbable sutures. All patients had a tracheotomy and a gastric tube (G-tube) placed during surgery. The patient demographics are shown in Table 1. The patients were further assessed through analyzing improvement in tongue mobility and esophageal transfer.


<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Site</th>
<th>Stage (TNM)</th>
<th>Surgery</th>
<th>Reconstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>63</td>
<td>BOT</td>
<td>T1N2M0</td>
<td>PG, MRND</td>
<td>Primary closure</td>
</tr>
<tr>
<td>2</td>
<td>57</td>
<td>Mandible</td>
<td>T4N0M0</td>
<td>SM, MRND</td>
<td>Free flap</td>
</tr>
<tr>
<td>3</td>
<td>36</td>
<td>Oral tongue</td>
<td>T1N1M0</td>
<td>PG, MRND</td>
<td>Primary closure</td>
</tr>
<tr>
<td>4</td>
<td>67</td>
<td>Tongue</td>
<td>T1N2M0</td>
<td>PP, MRND</td>
<td>Primary Closure</td>
</tr>
</tbody>
</table>

Results

Before using the MS in the present clinical application, we conducted a series of tests to demonstrate that their electrical performance and reliability would not be affected by exposure to the anticipated gamma radiation treatments of about 70 Gy cumulative exposures. The MS contains a custom integrated circuit chip built using a commercial 0.35 µ CMOS process, which is susceptible to damage from both high rates and high cumulative doses of radiation [22]. The electrical outputs of three MS implants were measured over their full range of parameters (pulse current 0.5-31.5 mA, duration 8-512 µs, and frequency 1-200 pps) in a specially instrumented saline bath. They were implanted into a Filet mignon piece of beef with orthogonal orientations so that the beam would pass normal to the plane of the chip in one device and tangential to the plane of the chip along the length and breadth of the chip respectively in the other devices as shown in Figure 2. This phantom was placed in the radiation chamber of a clinical gamma source calibrated to 5485 rad/h and exposed for 77 minutes to achieve a 70 Gy total dose. The devices were retested for electrical function on the same day and again 10 weeks later. They were then implanted in a fresh piece of meat in the same orientations and subjected to a second 70 Gy irradiation and immediate retest. Thus each implant received 140 Gy radiations. All devices functioned within specification at all test intervals. There was a tendency for the relationship between the commanded and measured output current to decline by up to 20% immediately after irradiation and then to recover over time post irradiation. This is consistent with a small shift in threshold for linear transistors with thick gate oxides due to initial formation and then spontaneous annealing of electron shifts in the semiconductor crystals [23].

During MRND, the MS is implanted above the left hypoglossal nerve and secured in position using sutures in all patients (Figure 3). Only one of the four patients completed the study but stimulation thresholds for visible twitch contractions were obtained in three patients. Patient #1 was too ill post-operatively to participate and died at home during the fourth post-operative week with acute myocardial infarction. Patient #2 had a recurrence of the tumor requiring additional surgery but did use the stimulation briefly. Histopathology in patient #3 demonstrated early stage disease with no lymph node metastases so a decision was made not to irradiate. Patient #4 started CRT within 3-4 weeks after surgery. Stimulation of the MS implant began before starting CRT. Two sets of stimulation protocols were available depending on the patient’s tolerance for muscle contractions: low (low frequency, supramaximal twitch) and high (strong, fused contractions - 10-30 pps). Stimulus strength for both was set at about 3 times threshold to assure complete recruitment of all motor units in the target muscles.

The implant receives both power and digital command signals via an external inductive coil held over the device by a modified soft cervical collar (Figure 4). The command signals specify the address of the implant that should respond to the pulse current (0.5-31.5 mA; 14 V compliance) and duration (8-512 microseconds) for a single output pulse. The coil is connected to a small control box (Personal Trainer) that allows the patient to manually start and stop any of three stimulation programs that are prescribed by the physician or therapist (Figure 4). During out-patient visits, the Personal Trainer is connected to a portable PC running a Windows program that enables testing the implant, monitoring usage information stored in the Personal Trainer, and developing new or modified stimulation programs that can be down-loaded into the Personal Trainer for use at home. Both patients quickly learned and reliably used the prescribed stimulation at home. High stimulation was used for both patients to achieve maximal activation and strong contraction of the muscles of tongue and laryngeal elevation. To prevent fatigue, the system was programmed with an “on and off time” schedule for the strong, intermittent contractions lasting 2-3s every 5-6s. Stimulus strength was ramped up...
and down over ~0.5 s for comfort. Patients were instructed to apply the stimulation three times daily during the entire course of radiation. Each session lasted for 20 minutes with a total stimulation time of one hour per day. Typically, they stimulated the implant before breakfast, lunch and dinner.

Discussion

Neuromuscular electrical stimulation (NMES) designed to stimulate peripheral and sensory nerves are gradually becoming a recognized treatment option for neuro-rehabilitation. There is growing scientific evidence of the benefit of NMES. The MS technology platform consists of individual, minimally invasive and low-cost implants that can be used to prevent dysphagia in HNC patients. MS is a new class of generic wireless injectable device which is placed near nerves to deliver precisely metered stimulation pulses. One or more implants receive power and individually addressed command signals by inductive coupling from an external antenna [15,17].

One of the concerns regarding electrical stimulation is whether it enhances tumor growth. Epidemiological studies have suggested that long-term exposure to high electromagnetic fields (EMF) may increase the incidence of several cancers [24-26].

Although a variety of biological responses may occur during exposure to exogenous EMF, there is no data that demonstrates increased risk of carcinogenesis under EMF exposure [27]. Shi et al studied this subject extensively and established that when cells were exposed to power line frequency EMF for a prolonged period of time, the critical events of cancer formation did not take place [28]. For the 480 kHz RF frequency used to power the MS implants, almost no energy is absorbed by body tissues. We have used a combined approach of TST and transcutaneous NMES (tNMES) for rehabilitation of dysphagia in HNC patients for the last four years with encouraging results. Survival or disease recurrence has not been affected by tNMES in these patients. However, we encountered a few limitations of tNMES during this study period that prompted us to use MS in HNC patients. Some patients complain of discomfort due to activation of cutaneous afferents during tNMES. The current delivered by the tNMES device provides sub-optimal stimulation of the neuromuscular complex because the motor axons that must be activated are at a substantial distance from the surface electrodes. In addition, patients have to undergo lengthy therapy in the office making this approach more expensive. The MS implant technology has the potential to circumvent the limitations of TST and tNMES. The treatment of dysphagia responds best to daily treatment. Transporting patients daily to clinics and using professional personnel to administer treatment is expensive and quite challenging for the family. The permanently implanted and telemetrically operated MS avoids these problems. This approach has the potential to improve patient compliance and make swallowing rehabilitation more cost-effective.

Conclusion

The present study demonstrated that the MS is a safe implant to use during RT. The performance of the implant is not affected by RT. Patients found it easy to self-administer daily NMES at home and compliance with prescribed treatment was high. MS provides robust contraction of muscles of the tongue and laryngeal elevations without inducing uncomfortable sensations.

Acknowledgement

The MS devices were built at and provided by the Alfred Mann Institute for Biomedical Engineering at the University of Southern California, which sponsored this clinical trial.
References